Verbatim response from Perplexity
The brand-name Zepbound is generally worth the extra cost for most people because it is FDA-approved, extensively studied in clinical trials, and manufactured under strict quality controls, whereas compounded tirzepatide lacks FDA approval and has unverified safety and efficacy [4][5]. While compounded versions are significantly cheaper (typically $150–$400 per month) compared to the brand’s net price (estimated around $5,200+ annually), the FDA explicitly advises that cost alone is not a valid reason to use a compounded medication when an FDA-approved option like Zepbound is available [5][6].
Compounded tirzepatide carries significant risks, including dosing errors, contamination, and the use of unverified or lower-quality ingredients, and it may contain additional inactive ingredients (like B-vitamins or L-carnitine) not found in Zepbound [4][5]. Additionally, compounded products are generally not covered by insurance [5], while Zepbound may be covered if your plan includes weight-loss medications [4].
However, if you are facing high costs, you may consider LillyDirect, Eli Lilly’s official patient-access program, which offers single-dose Zepbound vials and Kwikpens for $299–$449 per month, significantly reducing the price gap with compounded options [6]. For most patients, the predictable effects, consistent side-effect profile, and proven health benefits (such as reduced diabetes and cardiovascular complications) of Zepbound justify the higher cost [1][2].
Recommendation: Choose Zepbound (via LillyDirect if cost is a concern) unless you have a specific medical need for compounding (e.g., an allergy to an inactive ingredient in Zepbound), as advised by the FDA [5].